BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol 2020;15:449-66. [PMID: 32725437 DOI: 10.1007/s11523-020-00738-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Gatti M, Raschi E, Moretti U, Ardizzoni A, Poluzzi E, Diemberger I. Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel) 2021;9:19. [PMID: 33406694 DOI: 10.3390/vaccines9010019] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H, Shah R, Volckmar AL, Lusky F, Diekmann L, Liersch S, Faehling M, Muley T, Kriegsmann M, Benesova K, Stenzinger A, Thomas M, Christopoulos P. Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2021;11:703893. [PMID: 34268127 DOI: 10.3389/fonc.2021.703893] [Reference Citation Analysis]
3 Fusaroli M, Raschi E, Gatti M, De Ponti F, Poluzzi E. Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System. Front Pharmacol 2021;12:740707. [PMID: 34955821 DOI: 10.3389/fphar.2021.740707] [Reference Citation Analysis]
4 Han N, Oh JM, Kim IW. Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems. Ther Clin Risk Manag 2021;17:877-87. [PMID: 34456568 DOI: 10.2147/TCRM.S321789] [Reference Citation Analysis]
5 Abdel-Rahman O. Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US FDA adverse event reporting system. Immunotherapy 2021;13:1407-17. [PMID: 34709083 DOI: 10.2217/imt-2021-0068] [Reference Citation Analysis]
6 Filippini DM, Gatti M, Di Martino V, Cavalieri S, Fusaroli M, Ardizzoni A, Raschi E, Licitra L. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. Int J Cancer 2021;149:675-83. [PMID: 33844854 DOI: 10.1002/ijc.33592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Khouri C, Revol B, Lepelley M, Mouffak A, Bernardeau C, Salvo F, Pariente A, Roustit M, Cracowski JL. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. J Clin Epidemiol 2021:S0895-4356(21)00228-6. [PMID: 34329725 DOI: 10.1016/j.jclinepi.2021.07.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Noseda R, Bonaldo G, Motola D, Stathis A, Ceschi A. Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase. Cancers (Basel) 2021;13:1131. [PMID: 33800813 DOI: 10.3390/cancers13051131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ogawa K, Kozuka Y, Uno H, Utsumi K, Noyori O, Hosoki R. Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database. Clin Drug Investig 2021;41:615-27. [PMID: 34110613 DOI: 10.1007/s40261-021-01042-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 da Silva GFM, Landim JIVD, Dos Santos Brasil LT, Plens ICM, Silva ALC, Scheinberg MA, Rocha FAC. Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey. Rheumatol Int 2021;41:939-42. [PMID: 32767082 DOI: 10.1007/s00296-020-04674-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C. Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals (Basel) 2021;14:738. [PMID: 34451835 DOI: 10.3390/ph14080738] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Barac A, Sharon E. From Detecting Signals to Understanding Cardiovascular Toxicities of Cancer Therapies: All the Light We Could See. J Am Coll Cardiol 2021;78:1814-6. [PMID: 34711340 DOI: 10.1016/j.jacc.2021.09.008] [Reference Citation Analysis]
13 Goldman A, Raschi E, Cukierman-Yaffe T, Dankner R, Shouval R, Shechter M, Ben-Zvi I, Gerstein HC, Maor E. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. Eur J Prev Cardiol 2021:zwab209. [PMID: 34897409 DOI: 10.1093/eurjpc/zwab209] [Reference Citation Analysis]
14 Chen C, Wu B, Zhang C, Xu T. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol 2021;95:107498. [PMID: 33725634 DOI: 10.1016/j.intimp.2021.107498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Reynolds KL, Arora S, Elayavilli RK, Louv WC, Schaller TH, Khandelwal A, Rothenberg M, Khozin S, Guidon AC, Dougan M, Zubiri L, Petrillo L, Sise ME, Villani AC, Johnson DB, Rahma O, Sharon E. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. J Immunother Cancer 2021;9:e002896. [PMID: 34215691 DOI: 10.1136/jitc-2021-002896] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Goldman A, Bomze D, Dankner R, Fourey D, Boursi B, Arad M, Maor E. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study. Target Oncol 2021;16:471-83. [PMID: 33970401 DOI: 10.1007/s11523-021-00817-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yang Y, Xu L, Wang D, Hui B, Li X, Zhou Y, Chen X, Gu Y. Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report. Immunotherapy 2021. [PMID: 34369830 DOI: 10.2217/imt-2020-0327] [Reference Citation Analysis]
18 Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, Steingart RM, Mahmood SS, Schaffer WL, Perales MA, Shouval R. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J Am Coll Cardiol 2021;78:1800-13. [PMID: 34711339 DOI: 10.1016/j.jacc.2021.08.044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cao J, Li J, Yang X, Li P, Yao Z, Han D, Ying L, Wang L, Tian J. Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer. Cancer Med 2021;10:5375-91. [PMID: 34165261 DOI: 10.1002/cam4.4071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Ma R, Wang Q, Meng D, Li K, Zhang Y. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer 2021;21:38. [PMID: 33413213 DOI: 10.1186/s12885-020-07741-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Aiello V, Fusaroli M, Raschi E, Palazzini M, Hu L, Barbuto S, Poluzzi E, Capelli I. Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry. Kidney Int Rep 2021;6:2472-7. [PMID: 34514208 DOI: 10.1016/j.ekir.2021.06.028] [Reference Citation Analysis]
22 Abdayem P, Planchard D. Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Expert Opin Drug Saf 2021;20:651-67. [PMID: 33393387 DOI: 10.1080/14740338.2021.1867100] [Reference Citation Analysis]
23 Sun JY, Qu Q, Lou YX, Hua Y, Sun GZ, Sun W, Kong XQ. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. Int J Cardiol 2021;344:170-8. [PMID: 34563597 DOI: 10.1016/j.ijcard.2021.09.041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;:JCO2101440. [PMID: 34724392 DOI: 10.1200/JCO.21.01440] [Reference Citation Analysis]
25 Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. Cancers (Basel) 2021;13:1758. [PMID: 33917020 DOI: 10.3390/cancers13081758] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Noseda R, Ruinelli L, Gaag LCV, Ceschi A. Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study. Cancers (Basel) 2020;12:E3480. [PMID: 33238481 DOI: 10.3390/cancers12113480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]